(Q39124257)

9 September 2017

title

Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma (English)

1 reference

9 September 2017

1 reference

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

7

0 references

Ruben Niesvizky

14

object named as

Ruben Niesvizky

1 reference

9 September 2017

Ying Ou

1

1 reference

9 September 2017

Sameer Doshi

2

1 reference

9 September 2017

Anh Nguyen

3

1 reference

9 September 2017

Fredrik Jonsson

4

1 reference

9 September 2017

Sanjay Aggarwal

5

1 reference

9 September 2017

Kanya Rajangam

6

1 reference

9 September 2017

A Keith Stewart

8

1 reference

9 September 2017

Ashraf Badros

9

1 reference

9 September 2017

Kyriakos P Papadopoulos

10

1 reference

9 September 2017

David Siegel

11

1 reference

9 September 2017

Sundar Jagannath

12

1 reference

9 September 2017

Ravi Vij

13

1 reference

9 September 2017

Richard Graham

15

1 reference

9 September 2017

Jenn Visich

16

1 reference

9 September 2017

publication date

7 December 2016

1 reference

The Journal of Clinical Pharmacology

9 September 2017

published in

1 reference

9 September 2017

volume

57

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

663-677

1 reference

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

9 September 2017

cites work

1 reference

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

21 January 2018

1 reference

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

21 January 2018

1 reference

Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

21 January 2018

1 reference

Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

21 January 2018

1 reference

Extensions to the visual predictive check to facilitate model performance evaluation

21 January 2018

1 reference

Optimizing dosing of oncology drugs

21 January 2018

1 reference

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

21 January 2018

1 reference

A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors

21 January 2018

1 reference

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

21 January 2018

1 reference

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCPH.850

1 reference

9 September 2017

1 reference